Aardvark Therapeutics Unveils Positive Obesity Drug Data at ObesityWeek 2025

Reuters

10/22

<a href="https://laohu8.com/S/AARD">Aardvark Therapeutics</a> Unveils Positive Obesity Drug Data at ObesityWeek 2025

Aardvark Therapeutics Inc. announced that it will present new data from its pipeline programs at ObesityWeek 2025, scheduled for November 4-7, 2025, in Atlanta, Georgia. The company will share poster presentations on its investigational compounds, including ARD-101, a TAS2R pan-agonist evaluated for its effects on weight gain in mice and hunger reduction in adults with obesity, and WE-868, an isoflavonoid modulator of oxidative metabolism with therapeutic potential in obesity and diabetes. The data will be presented by Chief Scientific Officer Timothy Kieffer, Ph.D., and Chief Executive Officer Tien Lee, M.D., on November 4, 2025. Additionally, Aardvark will host an investor webinar on November 5, 2025, to discuss the presented data and provide updates on ARD-101's development in Prader-Willi Syndrome. The company will make an archived recording of the webinar available on its website for approximately one month after the event.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9549733-en) on October 22, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2577936183"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577936183\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577936183?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-22 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577936183","market":"us","top_or_hot":-1,"title":"Aardvark Therapeutics Unveils Positive Obesity Drug Data at ObesityWeek 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AARD\">Aardvark Therapeutics</a> Unveils Positive Obesity Drug Data at ObesityWeek 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aardvark <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced that it will present new data from its pipeline programs at ObesityWeek 2025, scheduled for November 4-7, 2025, in Atlanta, Georgia. The company will share poster presentations on its investigational compounds, including ARD-101, a TAS2R pan-agonist evaluated for its effects on weight gain in mice and hunger reduction in adults with obesity, and WE-868, an isoflavonoid modulator of oxidative metabolism with therapeutic potential in obesity and diabetes. The data will be presented by Chief Scientific Officer Timothy Kieffer, Ph.D., and Chief Executive Officer Tien Lee, M.D., on November 4, 2025. Additionally, Aardvark will host an investor webinar on November 5, 2025, to discuss the presented data and provide updates on ARD-101's development in Prader-Willi Syndrome. The company will make an archived recording of the webinar available on its website for approximately one month after the event.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9549733-en) on October 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aardvark Therapeutics Unveils Positive Obesity Drug Data at ObesityWeek 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAardvark Therapeutics Unveils Positive Obesity Drug Data at ObesityWeek 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-22 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AARD\">Aardvark Therapeutics</a> Unveils Positive Obesity Drug Data at ObesityWeek 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aardvark <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced that it will present new data from its pipeline programs at ObesityWeek 2025, scheduled for November 4-7, 2025, in Atlanta, Georgia. The company will share poster presentations on its investigational compounds, including ARD-101, a TAS2R pan-agonist evaluated for its effects on weight gain in mice and hunger reduction in adults with obesity, and WE-868, an isoflavonoid modulator of oxidative metabolism with therapeutic potential in obesity and diabetes. The data will be presented by Chief Scientific Officer Timothy Kieffer, Ph.D., and Chief Executive Officer Tien Lee, M.D., on November 4, 2025. Additionally, Aardvark will host an investor webinar on November 5, 2025, to discuss the presented data and provide updates on ARD-101's development in Prader-Willi Syndrome. The company will make an archived recording of the webinar available on its website for approximately one month after the event.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9549733-en) on October 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDLbLx9NK:1","article_id":"2577936183","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577936183","pubTimestamp":1761134427,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aardvark Therapeutics Inc. announced that it will present new data from its pipeline programs at ObesityWeek 2025, scheduled for November 4-7, 2025, in Atlanta, Georgia. The company will share poster presentations on its investigational compounds, including ARD-101, a TAS2R pan-agonist evaluated for its effects on weight gain in mice and hunger reduction in adults with obesity, and WE-868, an isoflavonoid modulator of oxidative metabolism with therapeutic potential in obesity and diabetes. The data will be presented by Chief Scientific Officer Timothy Kieffer, Ph.D., and Chief Executive Officer Tien Lee, M.D., on November 4, 2025. Additionally, Aardvark will host an investor webinar on November 5, 2025, to discuss the presented data and provide updates on ARD-101's development in Prader-Willi Syndrome. The company will make an archived recording of the webinar available on its website for approximately one month after the event.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","AARD":"Aardvark Therapeutics","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","NDAQ":"纳斯达克OMX交易所","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"Aardvark Therapeutics在2025年肥胖周上公布了积极的肥胖药物数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AARD":0.9,"NDAQ":0.9},"content_text":"Aardvark Therapeutics Unveils Positive Obesity Drug Data at ObesityWeek 2025\n    \n\n        Aardvark Therapeutics Inc. announced that it will present new data from its pipeline programs at ObesityWeek 2025, scheduled for November 4-7, 2025, in Atlanta, Georgia. The company will share poster presentations on its investigational compounds, including ARD-101, a TAS2R pan-agonist evaluated for its effects on weight gain in mice and hunger reduction in adults with obesity, and WE-868, an isoflavonoid modulator of oxidative metabolism with therapeutic potential in obesity and diabetes. The data will be presented by Chief Scientific Officer Timothy Kieffer, Ph.D., and Chief Executive Officer Tien Lee, M.D., on November 4, 2025. Additionally, Aardvark will host an investor webinar on November 5, 2025, to discuss the presented data and provide updates on ARD-101's development in Prader-Willi Syndrome. The company will make an archived recording of the webinar available on its website for approximately one month after the event.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9549733-en) on October 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}